Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$100.40 ▲ +3.36
(+3.46%)
MKT CAP: $6.31B • VOL: 1.17M
52W L $16 52W H $104
KOD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$234.4M | -$186.8M | -$277.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$230.0M | -$176.2M | -$260.5M |
| EBITDA (Normalized) | -$234.0M | -$186.5M | -$277.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$136.0M | -$117.3M | -$154.2M |
| Capital Expenditures (CapEx) | $506.0K | $375.0K | $0 |
| Free Cash Flow (FCF) | -$136.5M | -$117.7M | -$154.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -10.5% |
| Cash & Short-Term Equivalents | $209.9M | $168.1M | $381.8M |
| Total Debt (Short + Long Term) | $87.4M | $83.4M | $812.1M |
| Total Stockholders' Equity | $157.4M | $150.3M | $1.67B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KOD.